Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Xiaohui Wang 1,2,* , Zhengqiang Bao 1,2,* , Xiaoju Zhang 3,* , Fei Li 1 , Tianwen Lai 1 , Chao Cao 1 , Zhihua Chen 1 , Wen Li 1 , Huahao Shen 1,4 and Songmin Ying 1,2 1 Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Institute of Respiratory Diseases, Zhejiang University School of Medicine, Hangzhou, China 2 Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou, China 3 Department of Respiratory Medicine, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China 4 State Key Laboratory of Respiratory Diseases, Guangzhou, China * These authors have contributed equally to this manuscript Correspondence to: Songmin Ying, email: // Huahao Shen, email: // Keywords : PD-1, PD-L1, nivolumab, pembrolizumab, cancer Received : August 12, 2016 Accepted : March 01, 2017 Published : May 31, 2017 Abstract Background: PD-1/PD-L1 inhibitors have been implicated as potentially effective anti-cancer therapies. Some clinical randomized controlled trials (RCTs) have been completed for a variety of PD-1/PD-L1 inhibitors to treat various malignancies, and more RCTs are still under way. We carried out this systematic meta-analysis to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors. Methods: We searched PubMed, EMBASE, clinical trial registers, conference reports, and related reviews. Eligible RCTs that compared PD-1/PD-L1 inhibitors with other chemotherapy agents or placebo in solid tumor patients were included. For each RCT, progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), stable disease rate (SDR), progressive disease rate (PDR), and adverse events (AEs) were pooled for meta-analysis. Findings: Based on an analysis of 10 eligible RCTs, PD-1/PD-L1 inhibitors were found to significantly improve PFS (Hazard ratio (HR), 0.65; 95% confidence interval (CI) 0.53 to 0.79, P <0.001), OS (HR, 0.69; 95%CI 0.62 to 0.76, P <0.001), and ORR (Risk Ratio (RR) 2 . 92; 95% confidence interval (CI) 2.06 to 4.15, P <0.00001) in all populations, including melanoma and NSCLC subgroups. However, they failed to increase the DCR of cancer patients (RR 1.15; 95%CI 0.91 to 1.45, P =0.25). Furthermore, less AEs were observed in the PD-1/PD-L1 inhibitor groups than the control groups. Interpretation: PD-1 inhibitors are more effective for improving the PFS, OS, and ORR of cancer patients with little toxicity, despite having little effect on increasing of the DCR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · cited 2×
“There were 6 studies [23, 26-30] [23, 26-30] [25, 28-32] [25, 28-32] [25, 28-32] about melanoma, 3 studies were related to NSCLC treatment, and 1 study was on renal-cell carcinoma.”
BackgroundMethodNivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756 · cited 1×
“After carefully reading the full texts of the remaining 71 articles, 10 eligible studies [21-30] met the inclusion criteria, as shown in Figure 1.”
MethodTaube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Cited by
Wang, G.-Z., Zhang, L., Zhao, X.-C., Gao, S.-H., Qu, L.-W., Yu, H., Fang, W.-F., Zhou, Y.-C., Liang, F., Zhang, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08887-7 · Cited by 213
Huo, J.-L., Wang, Y.-T., Fu, W.-J., Lu, N., & Liu, Z.-S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956090 · Cited by 176
Kriegsman, B. A., Vangala, P., Chen, B. J., Meraner, P., Brass, A. L., Garber, M., & Rock, K. L. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900475 · Cited by 114
Metadata
- Authors
- Wang, X., Bao, Z., Zhang, X., Li, F., Lai, T., Cao, C., Chen, Z., Li, W., Shen, H., & Ying, S.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-05-31
- Volume
- 8
- Issue
- 35
- Pages
- 59901-59914
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2619738298
- Cited by
- 75
- References
- 5
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.